Clinical Trials | ||
Updates from the National Cancer Institute | ||
Clinical Trials News | ||
Trial Highlights Complexities of Targeted Therapy for Pancreatic Cancer Olaparib (Lynparza) may be beneficial for some people with advanced pancreatic cancer who have inherited mutations in the BRCA1 or BRCA2genes, according to results from the POLO trial. | ||
More Treatment Options Emerging for Some Men with Metastatic Prostate Cancer In two large clinical trials, the drugs enzalutamide (Xtandi) and apalutamide (Erleada), respectively, combined with androgen deprivation therapy, improved the survival of men with metastatic prostate cancer that still responds to hormone-suppressing therapies. | ||
Combination Therapy with Venetoclax Approved for Chronic Lymphocytic Leukemia The Food and Drug Administration has approved venetoclax (Venclexta) in combination with obinutuzumab (Gazyva) for the initial treatment of adults with chronic lymphocytic leukemia or small lymphocytic lymphoma. The new approval is based on results from a phase 3 clinical trial. | ||
Drug Shows Promise in Slowing Progression of Smoldering Myeloma to Cancer The drug lenalidomide (Revlimid) may delay the progression of smoldering myeloma to multiple myeloma, according to preliminary results from an NCI-supported clinical trial. | ||
T-DM1 Approval Expanded to Include Early-Stage HER2-Positive Breast Cancer FDA has expanded the approved use of the drug ado-trastuzumab emtansine (Kadcyla), also called T-DM1, to include adjuvant treatment in some women with early-stage HER2-positive breast cancer based on findings from a large clinical trial. | ||
Clinical Trials Information for Patients and Caregivers | ||
Insurance Coverage and Clinical Trials Although the experimental treatment given in clinical trials is often free, participants are usually required to pay usual care costs. This page discusses what clinical trial costs health insurance plans are required to cover, what conditions must be met for insurance to cover these cost, and what costs plans may not cover. | ||
Federal Government Programs Some federal programs may help pay the costs of care in clinical trials for eligible beneficiaries. This page describes those programs and who they can help. | ||
Find NCI-Supported Clinical Trials Use our search form to find a clinical trial or other research study that may be right for you or a loved one. | ||
NCI-Supported Clinical Trials That Are Recruiting Patients | ||
Basket Trial Seeks to Improve Understanding of ALK-positive Lung Cancer This phase 2 trial is testing several different drugs and biomarkers in patients with late-stage, ALK-positive non-small cell lung cancer whose tumors are resistant to previous ALK inhibitor therapy. Doctors will assess the overall response rates in patients in the trial’s nine treatment groups. | ||
Testing Different Conditioning Therapies Before Stem-Cell Transplant This phase 2 trial will test a new method for blood-forming stem cell transplantation from healthy donors to patients with a rare type of lymphoma. Patients with relapsed or resistant peripheral T-cell lymphoma will undergo either reduced-intensity conditioning therapy or immunosuppression only prior to transplantation with donated blood or bone marrow stem cells. | ||
Combination Therapy for Recurrent Head-and-Neck Cancer This phase 1 trial is testing the drug birinapant combined with intensity-modulated radiation therapy (IMRT) for patients with head-and-neck squamous cell carcinoma that has recurred after treatment with chemoradiotherapy. Researchers want to assess the side effects and determine the best dose of birinapant when combined with IMRT for future clinical trials |
Los avances de la medicina en el campo de la genética, por ende de la herencia, están modificando el paisaje del conocimiento médico de las enfermedades. Este BLOG intenta informar acerca de los avances proveyendo orientación al enfermo y su familia así como información científica al profesional del equipo de salud de habla hispana.
sábado, 29 de junio de 2019
Clinical Trials Update from NCI, June 2019
Clinical Trials Update from NCI, June 2019
No hay comentarios:
Publicar un comentario